Glaucoma

Latest News


CME Content


The World Glaucoma Day inspired glaucoma specialists around the world to rally local support in order to undertake an enormous task: to reduce the number of people who are unnecessarily going blind from a treatable condition.

QLT Plug Delivery, Inc. has demonstrated proof of concept of its punctal plug drug delivery technology, showing that it is both well tolerated and effective at lowering intraocular pressure (IOP).

Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.

Three separate studies on eye health examine the role of antioxidant supplements, the relationship of visual acuity and mortality, and the causes of glaucoma in the May 2008 issue of Ophthalmology, the journal of the American Academy of Ophthalmology.

The Collaborative Initial Glaucoma Treatment Study (CIGTS) showed that substantially lowering IOP, whether through medication or surgery, can prevent vision loss. One of the major trials of recent years, CIGTS also showed that surgery was an effective first-line treatment and had important findings on quality of life.

The iCare tonometer (Tiolat) has been approved for use in China by the country's State Food and Drug Administration (SFDA); the tonometer is now approved in every major global market.

Paediatric cataract surgery, particularly when performed in patients under the age of nine months, entails a substantial risk of post-surgical glaucoma, according to a study published in the January 2008 issue of Investigative Ophthalmology and Visual Science.

Bottles of infected eye drops are more likely to be contaminated with bacteria at the bottle tip and not within the solution, according to a study presented at this year's American Society of Cataract and Refractive Surgery (ASCRS) meeting.

The Tube versus Trabeculectomy (TVT) Study found that nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony and reoperation for glaucoma than trabeculectomy with mitomycin C (MMC) during the first year of follow-up.

Hi-Tech Pharmacal Co., Inc. has announced that the FDA has granted tentative approval to the company's Abbreviated New Drug Application (ANDA) for dorzolamide hydrochloride with timolol maleate ophthalmic solution, the generic equivalent of Merck's Cosopt.

Intraocular pressure (IOP) lowering drugs are more effective in eyes with low central corneal thickness (CCT) than those with high CCT, according to a study published in the March issue of Journal of Glaucoma.